Canaccord Genuity Maintains Buy on DexCom, Maintains $145 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on DexCom (NASDAQ:DXCM) with a $145 price target.

July 23, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on DexCom with a $145 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a specific price target of $145 by a reputable analyst suggests positive sentiment and confidence in DexCom's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100